Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | VP, Regulatory Affairs | July 28, 2021 | July 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date July 28, 2021 · Filed July 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2031-07-27 | Direct | 25,000 |
Reported balance
After 2021-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-28 · Grant · Acquired 25,000 · Balance 25,000 F1: Vests in sixteen nearly equal quarterly installments over four years. |
| Voting Common Shares, no par value per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2021-07-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in sixteen nearly equal quarterly installments over four years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2021 Filed Jul 30, 2021 01:18 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001235802-21-000094 · primary_doc.xml · derivative · entry 2 Gilman Sydney A. · CIK 0001793016 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2031-07-27 F1 · derivative.exercise_date: Vests in sixteen nearly equal quarterly installments over four years. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:36 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001235802-20-000055 · primary_doc.xml · derivative · entry 2 Gilman Sydney A. · CIK 0001793016 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Shares · 17,500 shares Expires 2030-05-31 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments commencing on September 1, 2020. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:13 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001235802-19-000131 · primary_doc.xml · derivative · entry 2 Gilman Sydney A. · CIK 0001793016 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-10-31 F1 · derivative.exercise_date: Vests in twelve nearly equal quarterly installments over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.